This probe is available from Cayman Chemical , Tocris and Sigma-Aldrich.
The control may be requested by clicking here.
Probe | Negative control | |
![]() |
| ![]() |
OICR-9429 |
| OICR-0547 |
A collaboration between the SGC and The Drug Discovery Program at the Ontario Institute for Cancer Research (OICR) has resulted in the discovery of OICR-9429, a chemical probe for WDR5, a component of several chromatin regulatory complexes including the MLL1 (Mixed Lineage Leukemia 1) complex. OICR-9429 is a potent antagonist of the interaction of WDR5 with peptide regions of MLL and Histone 3 with >100-fold selectivity over other chromatin “reader” domains, methyltransferases, and other non-epigenetic targets. OICR-9429 has been shown to bind to WDR5 with KD values of 24 nM (Biacore) and 52 nM (ITC). OICR-9429 also disrupts the interaction of WDR5 with MLL1 and RbBP5 in cells with IC50 values below 1 µM.
A closely-related compound, OICR-0547, does not show WDR5 antagonism, and can therefore be used as a negative control in phenotypic assays.
Probe | Negative control | |
![]() |
| ![]() |
OICR-9429 |
| OICR-0547 |
Physical and chemical properties for OICR-9429 | |
Molecular weight | 555.2 |
Molecular formula | C29H32F3N5O3 |
IUPAC name | 5-((2-(4-methyl-piperazin-1-yl)-5-(3-((morpholin-4-yl)-methyl)-phenyl)-phenylamino)-formyl)-4-(trifluoro-methyl)-1,2-dihydro-pyridin-2-one |
MollogP | 3.382 |
PSA | 65.34 |
No. of chiral centres | 0 |
No. of rotatable bonds | 8 |
No. of hydrogen bond acceptors | 7 |
No. of hydrogen bond donors | 2 |
Physical and chemical properties for OICR-0547 (Negative Control) | |
Molecular weight | 542.2 |
Molecular formula | C28H29F3N4O4 |
IUPAC name | 5-((2-(morpholin-4-yl)-5-(3-((morpholin-4-yl)-methyl)-phenyl)-phenylamino)-formyl)-4-(trifluoro-methyl)-1,2-dihydro-pyridin-2-one |
MollogP | 3.331 |
PSA | 69.77 |
No. of chiral centres | 0 |
No. of rotatable bonds | 8 |
No. of hydrogen bond acceptors | 7 |
No. of hydrogen bond donors | 2 |
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPa N-terminal leukemia ,Florian Grebien, Masoud Vedadi, Matthäus Getlik, Roberto Giambruno, Amit Grover, Roberto Avellino, Anna Skucha, Sarah Vittori, Ekaterina Kuznetsova, David Smil, Dalia Barsyte-Lovejoy, Fengling Li, Gennadiy Poda, Matthieu Schapira, Hong Wu, Aiping Dong, Guillermo Senisterra, Alexey Stukalov, Kilian V M Huber,Andreas Schönegger, Richard Marcellus, Martin Bilban, Christoph Bock, Peter J Brown, Johannes Zuber, Keiryn L Bennett, Rima Al-awar, Ruud Delwel, Claus Nerlov, Cheryl H Arrowsmith & Giulio Superti-Furga. Nature Chemical Biology. 10.1038/nchembio.1859
Main features